# Celldex Therapeutics (CLDX) — Earnings

CLDX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/cldx/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q3 2025 |
| Period end | Sep 30, 2025 |
| EPS actual | −$1.01 |
| EPS estimate | −$0.90 |
| EPS surprise | −12.28% |
| Revenue surprise | −100.00% |
| Revenue | $0.00 |
| Revenue estimate | $985,818.00 |
| Reported | Nov 10, 2025 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/744218/000110465925109137/cldx-20250930x10q.htm) |

Celldex reported Q3 2025 results on November 10, 2025. It posted a loss of $1.01 per share, wider than the expected loss of $0.90, a miss of 12.28%. No revenue figure was reported, against an estimate of about $986,000. A year earlier, in Q3 2024, the loss was $0.64 per share, so the loss widened by about 58%.

Every quarter in the table is a loss. Annual losses grew from $1.64 per share in 2021 to $2.39 in 2022 and $2.91 in 2023, then narrowed to $2.45 in 2024. The first nine months of 2025 lost $2.67, about 53% more than the same period of 2024. Q3 2025 is the largest quarterly loss in the table. Revenue is small and uneven, ranging from $153,000 to $4.1 million a quarter, with $7.1 million for all of 2024. Celldex beat the EPS estimate in 9 of the last 20 quarters and missed in 11.

The table has no report after November 2025. In 2022 through 2025, Celldex reported Q4 between February 26 and February 28. A newer report would show whether the losses kept widening into the end of 2025.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q3 2025 | Nov 10, 2025 | −$0.90 | −$1.01 | -12.28% | $985,818.00 | — |
| Q2 2025 | Aug 7, 2025 | −$0.86 | −$0.85 | 0.68% | $1.0M | $730,000.00 |
| Q1 2025 | May 8, 2025 | −$0.76 | −$0.81 | -7.28% | $997,600.00 | $695,000.00 |
| Q4 2024 | Feb 27, 2025 | −$0.74 | −$0.71 | 3.72% | $1.0M | $1.2M |
| Q3 2024 | Nov 6, 2024 | −$0.67 | −$0.64 | 4.83% | $835,556.00 | $3.2M |
| Q2 2024 | Aug 8, 2024 | −$0.59 | −$0.54 | 8.13% | $854,286.00 | $2.5M |
| Q1 2024 | May 6, 2024 | −$0.69 | −$0.56 | 19.18% | $809,000.00 | $200,000.00 |
| Q4 2023 | Feb 26, 2024 | −$0.73 | −$0.83 | -13.11% | $1.4M | $4.1M |
| Q3 2023 | Nov 2, 2023 | −$0.68 | −$0.81 | -19.12% | $583,333.00 | $1.5M |
| Q2 2023 | Aug 8, 2023 | −$0.66 | −$0.65 | 1.26% | $528,000.00 | $268,000.00 |
| Q1 2023 | May 4, 2023 | −$0.62 | −$0.62 | 0.32% | $410,000.00 | $967,000.00 |
| Q4 2022 | Feb 28, 2023 | −$0.59 | −$0.56 | 5.08% | $264,000.00 | $1.6M |
| Q3 2022 | Nov 9, 2022 | −$0.57 | −$0.57 | -0.58% | $360,000.00 | $407,000.00 |
| Q2 2022 | Aug 8, 2022 | −$0.46 | −$0.77 | -67.39% | $400,000.00 | $163,000.00 |
| Q1 2022 | May 5, 2022 | −$0.45 | −$0.49 | -9.87% | $560,000.00 | $174,000.00 |
| Q4 2021 | Feb 28, 2022 | −$0.42 | −$0.43 | -3.19% | $1.0M | $333,000.00 |
| Q3 2021 | Nov 9, 2021 | −$0.36 | −$0.45 | -26.76% | $1.2M | $153,000.00 |
| Q2 2021 | Aug 5, 2021 | −$0.40 | −$0.34 | 15.00% | $643,333.00 | $3.5M |
| Q1 2021 | May 6, 2021 | −$0.35 | −$0.42 | -21.74% | $965,000.00 | $685,000.00 |
| Q4 2020 | Mar 29, 2021 | −$0.37 | −$0.55 | -49.99% | $600,000.00 | $3.8M |

## Frequently Asked Questions

### When did Celldex Therapeutics (CLDX) last report earnings?

Celldex Therapeutics last reported on Nov 10, 2025, covering fiscal Q3 2025.

### Did CLDX beat earnings estimates?

No. Celldex Therapeutics reported EPS of −$1.01 for Q3 2025 against a −$0.90 estimate — a 12.28% miss.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).